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Virusneutralization isgovernedby thenumberof anti-
bodies that bind a virion during the cellular entry
process. Cellular and serum factors that interact
with antibodies have the potential to modulate
neutralization potency. Although the addition of
serum complement can increase the neutralizing
activity of antiviral antibodies in vitro, themechanism
and significance of this augmented potency in vivo
remain uncertain. Herein, we show that the comple-
ment component C1q increases the potency of anti-
bodies against West Nile virus by modulating the
stoichiometric requirements for neutralization. The
addition of C1q does not result in virolysis but instead
reduces the number of antibodies that must bind
the virion to neutralize infectivity. For IgG subclasses
that bind C1q avidly, this reduced stoichiometric
threshold falls below the minimal number of anti-
bodies required for antibody-dependent enhance-
ment (ADE) of infection of cells expressing Fc-g
receptors (CD32) and explains how C1q restricts the
ADE of flavivirus infection.
INTRODUCTION
The development of antiviral antibodies is a critical aspect of
protection against viral infections. The mechanisms of anti-
body-mediated neutralization have been investigated for many
animal viruses and can be characterized as a ‘‘multiple-hit’’
phenomenon that requires engagement of a virion with a stoichi-
ometry that exceeds a required threshold number of antibodies
(Burnet et al., 1937; Burton et al., 2001; Della-Porta and West-
away, 1978). The factors that define the stoichiometric require-
ments for neutralization of different classes of viruses are
unknown, although the size of a virion correlates with estimates
of the number of antibodies required for neutralization (BurtonCell Hoet al., 2001). The mechanisms by which antibodies promote viral
clearance and protection from disease in vivo often extend
beyond their capacity to directly neutralize virus infectivity, and
include effector mechanisms mediated by the crystallizable
fragment (Fc) portion of the antibody molecule (Burton, 2002;
Nimmerjahn and Ravetch, 2008). These Fc-dependent effector
functions include the ability to trigger antibody-mediated cellular
cytotoxicity by Fc-g-receptor (Fc-gR)-bearing cells, facilitate
viral clearance by phagocytic cells, and fix complement (Nim-
merjahn and Ravetch, 2008; Ravetch and Bolland, 2001). Serum
complement has been hypothesized to increase the potency of
antibodies by promoting more efficient targeting of viruses for
phagocytic destruction following opsonization, generating
membrane attack complexes on the virion that lead to lysis in
solution, and directly enhancing the neutralizing activity of anti-
bodies (Volanakis, 2002; Zinkernagel et al., 2001). How comple-
ment augments the neutralization potential of antibodies has not
been established, nor has it been determined whether this trans-
lates into increased potency in vivo. Indeed, a recent study of the
host factors required for protection from experimental simian
human immunodeficiency virus (SHIV) infection following
passive transfer of antibody has challenged the role of comple-
ment in the antiviral properties of neutralizing antibody in vivo
(Hessell et al., 2007).
Flaviviruses are a group of positive-strand RNA viruses of
global significance that cause severe encephalitic or hemor-
rhagic disease in humans (Mackenzie et al., 2004). Among
medically relevant flaviviruses, West Nile virus (WNV) is now
the primary cause of epidemic encephalitis in the United States
(Sejvar, 2007), and dengue virus (DENV) is the most common
mosquito-borne viral disease in the world (Kyle and Harris,
2008; Mackenzie et al., 2004). Flavivirus virions incorporate
180 envelope (E) proteins that orchestrate several steps of the
virus life cycle including virus assembly and egress, attachment
and entry of target cells, and the low pH-dependent fusion
between viral and endosomal membranes (Mukhopadhyay
et al., 2005). The E protein is also a major target of antiviral anti-
bodies elicited after flavivirus infection (Roehrig, 2003). Indeed,
passive prophylaxis of anti-E protein antibodies confersst & Microbe 6, 381–391, October 22, 2009 ª2009 Elsevier Inc. 381
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et al., 2003; Diamond et al., 2003; Roehrig et al., 2001). Further-
more, some anti-E protein antibodies have significant thera-
peutic potential; administration of a potently neutralizing mono-
clonal antibody (mAb) can protect WNV-infected mice from
death even after virus has spread into the central nervous system
(Gould et al., 2005; Morrey et al., 2006, 2007; Oliphant et al.,
2005; Samuel et al., 2007). Thus, the induction of a potent anti-
viral humoral response is a primary goal for the development of
vaccines against flaviviruses (Whitehead et al., 2007).
The presence of virus-specific antibodies, however, under
certain conditions may adversely impact the outcome of flavivi-
rus infection (Halstead, 2003). Infants with low circulating
amounts of maternal anti-DENV antibodies are at an increased
risk of severe disease following DENV infection (Chau et al.,
2008; Kliks et al., 1988). In addition, the immune response eli-
cited by primary DENV infection not only fails to protect from
a secondary infection with a heterologous serotype of DENV
but may exacerbate disease (reviewed by Halstead, 2003). While
the underlying mechanisms and circumstances that promote
more severe clinical manifestations of infection have not yet
been established in vivo, one prevailing hypothesis is that anti-
bodies increase viral burden by increasing the efficiency of infec-
tion of Fc-gR-bearing cells. This phenomenon has been studied
extensively and is termed antibody-dependent enhancement
(ADE) of infection (Halstead, 2003).
The atomic structure of the E protein and its pseudoicosahedral
arrangement on the virion has been determined for several flavi-
viruses (Mukhopadhyay et al., 2005), including WNV (Kanai et al.,
2006; Nybakken et al., 2006). These insights, coupled with the
availability of a large number of well-characterized mAbs (Oli-
phant et al., 2005, 2006; Sanchez et al., 2005; Throsby et al.,
2006) and a robust pathogenesis model in mice (reviewed by
Samuel and Diamond, 2006), make WNV an excellent system
for investigating principles that determine the potency of neutral-
izing antibodies (Pierson et al., 2008). Studies of the mechanisms
of antibody-mediated neutralization of WNV support a require-
ment for the engagement of flaviviruses by multiple antibodies
(Della-Porta and Westaway, 1978; Pierson et al., 2007). A stoi-
chiometric threshold of 30 antibodies is required to neutralize
WNV (Pierson et al., 2007). Neutralization potency is governed,
in part, by antibody affinity and the number of accessible epitopes
displayed on the virion. Because not all epitopes recognized by
antibodies are displayed equivalently on the virion (Oliphant
et al., 2006; Stiasny et al., 2006), some antibodies may not bind
virus particles with a stoichiometry that exceeds the neutraliza-
tion threshold, even at saturating concentrations (Nelson et al.,
2008;Piersonetal., 2007).Engagementof thevirionwithastoichi-
ometry below the neutralization threshold can promote ADE
(Morens et al., 1987; Pierson et al., 2007). Of interest, a single anti-
body bound to the virion is not sufficient to augment infection of
cells expressing Fc-gRIIA receptors. Instead, ADE requires the
binding of 15 antibodies to the virion (Pierson et al., 2007).
Thus, ADE occurs in a rather narrow window of antibody concen-
trations defined at the upper limit by the number of antibodies
required to neutralize infection, and at a lower limit by the number
of antibodies required for stable attachment to cells.
Herein, we sought to determine how complement modulates
the neutralizing activity of antibodies and whether this translates382 Cell Host & Microbe 6, 381–391, October 22, 2009 ª2009 Elsevieinto increased protection against WNV disease in vivo. We found
that binding of the complement component C1q is sufficient to
decrease the stoichiometric requirements for antibody neutrali-
zation. By reducing the threshold number of antibodies required
for neutralization, C1q allows virus inactivation at lower concen-
trations of antibody and also has significant implications for the
ability of an antibody to promote ADE. An improved under-
standing of the fundamental biochemical and molecular basis
of antibody neutralization may facilitate the development of
vaccination strategies that elicit a protective humoral response
with a reduced potential for ADE in vivo.
RESULTS
C1q Enhances the Neutralization Potency of Anti-WNV
Antibodies and Is Not Dependent upon Lysis of the Virion
To investigate how complement augments the potency of anti-
bodies, we employed a validated, quantitative approach for
measuring antibody-mediated neutralization in the presence
and absence of complement (Pierson et al., 2006, 2007). We
found that the neutralization potency of the murine IgG2b mAb
E16 (Nybakken et al., 2005; Oliphant et al., 2005), which recog-
nizes an epitope on the lateral ridge of domain III (DIII-LR) of
WNV E, was significantly improved (8.8-fold, p = 0.001, n = 5)
following the addition of fresh, but not heat-inactivated, mouse
serum (Figure 1A). Experiments using C1q-deficient mouse
serum or purified human C1q protein demonstrate that this
component of the classical complement pathway was necessary
and sufficient for the augmented neutralization potency of anti-
WNV antibodies in vitro (Figure 1B), results that agree with prior
studies with influenza virus (Feng et al., 2002; Mozdzanowska
et al., 2006). As expected, the addition of other purified comple-
ment components (e.g., human C5) had no effect on neutraliza-
tion by E16 (see Figure S1 available online). Increased neutraliza-
tion in the presence of purified C1q was also observed using
mouse and human WNV-immune polyclonal sera (Figures 1C
and D and Figure S2). Increased antibody potency was not
dependent upon antibody-dependent complement-mediated
virolysis, as fresh C3/ and C5/ mouse serum equivalently
increased neutralization potency (Figure 1B, data not shown).
C1q Reduces the Number of Antibodies Required
for Neutralization
Previous studies of the stoichiometric requirements for WNV
neutralization suggested that 30 E16 mAbs are required to
neutralize virus infectivity (Pierson et al., 2007). In this context,
at least two mechanisms for C1q-augmented neutralization are
possible. (1) Hexameric C1q might increase antibody avidity by
virtue of its ability to simultaneously bind multiple antibodies
via their Fc domain. A higher avidity would increase the number
of antibodies docked onto a virion at any given concentration of
antibody, which in turn would allow engagement of the virion
with a stoichiometry that exceeds the required neutralization
threshold at lower concentrations of antibody. (2) Alternatively,
C1q could directly modulate the stoichiometric threshold
required for neutralization, thereby changing the number of
antibodies required to block infection. This would allow neutral-
ization following engagement of a smaller fraction of epitopes
on the virion. The neutralization potency of several classes ofr Inc.
Cell Host & Microbe
C1q Modulates WNV Neutralization RequirementsFigure 1. C1q Augments the Neutralization
Potency of Anti-WNV Antibodies
(A) Serial dilutions of E16 (murine IgG2b) were incu-
bated with WNV RVP in the presence of media, 5%
fresh or heat-inactivated mouse serum prior to
infection of Raji cells that express the attachment
factor DC-SIGNR (Davis et al., 2006). Forty hours
later, cells were fixed and analyzed by flow cytom-
etry for GFP expression.
(B) Experiments were performed as described in
(A), except mixtures of RVP and E16 were incu-
bated with C1q/ or C3/ fresh mouse serum,
or purified C1q (50 mg/mL).
(C and D) The impact of purified C1q on the
neutralizing activity of affinity-purified IgG from
naive or WNV-immune mouse serum (C) or conva-
lescent heat-inactivated human serum from WNV-
infected patients (D) was assayed as described in
(A). In all cases, data are expressed as infectivity
relative to conditions in the absence of antibody.
Error bars represent the standard error of the
mean. The number of independent replicates is
indicated in the text.anti-WNV antibodies, including those commonly elicited in
humans (Oliphant et al., 2007; Throsby et al., 2006), is limited
by the accessibility of their epitopes on the mature virion (Nelson
et al., 2008; Stiasny et al., 2006). A C1q-mediated reduction in
the number of antibodies required for protection provides a
mechanism for increasing the potency in vivo of antibodies
that recognize cryptic determinants and are poorly inhibitory
in vitro because they fail to bind the virion enough times to allow
for neutralization.
To distinguish between these possibilities, we investigated
how C1q modulates neutralization potency using a genetic
complementation approach that allows the number of epitopes
on individual virions to be experimentally manipulated (Pierson
et al., 2007). A series of WNV reporter virus particles (RVPs)
composed of wild-type (WT) E proteins, and a variant containing
a single mutation (T332K) in the DIII-LR epitope that abolishes
recognition by E16, were produced as described previously
(Pierson et al., 2007). The T332K mutant E protein incorporated
into these virions is not detectably bound by DIII-LR-specific
neutralizing antibodies; infection by virions composed solely of
this variant were not inhibited by any concentration of E16 in
the presence or absence of C1q (Figure 2A). Reducing the
number of intact DIII-LR epitopes on the virion resulted in the
appearance of a population of virus particles resistant to neutral-
ization even at saturating concentrations (200-fold greater than
the apparent KD (1.53 10
10 M) of E16 for the virion) (Figure 2A,
left panel, and Figure S3). For example, when neutralization
studies were performed using a population of virions that dis-
play, on average, 25% of the epitopes present on a WT virion
(25% WT RVPs), approximately half of the virions (54%, n = 10)
were resistant to neutralization by E16, in agreement with pub-
lished results with the DIII-LR-specific mAb E24 (Figure 2A, left
panel) (Pierson et al., 2007). This resistant fraction corresponds
to the proportion of virions in the population that do not incorpo-
rate a sufficient number of epitopes to allow for neutralization atCell Hosany concentration of antibody (Figure S3). For the population of
25% WT RVPs (which corresponds to an average of 30 epitopes/
virion), roughly half the virus particles incorporate 30 or more
intact epitopes and were neutralized, whereas half the virions
incorporate fewer epitopes and were not neutralized even
when all the epitopes on the virion were fully engaged by anti-
body (Figure 2A, left panel). Strikingly, the addition of C1q
reduced the resistant fraction roughly 8-fold (p < 0.001, n = 10)
for RVPs with 25% WT E proteins (Figure 2A, right panel, and
Figure 2B). Similar results were observed with the DIII-LR-
specific mAb E24 (Figure S4). Because all of the available
epitopes on virions in the resistant fraction are already bound
at high concentrations of E16 in the absence of C1q, the ability
to neutralize this population of virions in the presence of C1q
cannot be explained by a change in antibody avidity. Instead,
these results suggest the number of antibodies required for
neutralization is reduced in the presence of C1q (Figure S3). To
test this hypothesis further, we produced RVPs that incorporate
on average only a tenth of the epitopes present on a WT virion
(10% WT RVP; Figure 2A, corresponding to 12 E16 epitopes/
virion) and examined their sensitivity to neutralization by E16.
The majority of virions in the 10% WT RVP population were
sensitive to neutralization by E16 in the presence, but not the
absence, of C1q. If engagement of 12 epitopes was required
for neutralization in the presence of C1q, a resistant fraction of
50% would be predicted. Because the resistant fraction in
the presence of C1q is smaller (28%, n = 4; Figure 2B), the stoi-
chiometric threshold of neutralization in the presence of C1q
must be fewer than 12 antibodies per virion.
C1q-Dependent Modulation of Neutralization Potency
by Antibody Is Isotype Dependent
Different subclasses of IgG bind C1q with distinct affinities
(Bindon et al., 1988). Four IgG subclasses of a humanized
version of the E16 mAb (hu-E16) were engineered and testedt & Microbe 6, 381–391, October 22, 2009 ª2009 Elsevier Inc. 383
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Requirements for Neutralization
(A) WNV RVPs that differ with respect to the
number of DIII-LR epitopes incorporated into the
average virion were produced by genetic comple-
mentation. WNV RVPs that incorporate different
proportions of WT E proteins (indicated on the
right) were incubated with serial dilutions of murine
E16 in the absence (left panel) or presence (right
panel) of 50 mg/ml purified human C1q protein
prior to infection of Raji DC-SIGNR cells. Infection
was monitored using flow cytometry as described
in Figure 1.
(B) The size of the population of RVPs resistant to
neutralization by saturating concentrations of
murine E16 is summarized for RVPs composed
of 100%, 50%, 25%, and 10% WT E proteins.
The average of data from four to ten independent
experiments performed using four to six different
preparations of RVPs is shown; error bars display
the standard error of the mean.
(C) The size of the resistant fraction observed
following the incubation of RVPs composed of
25% WT E proteins with humanized isotypes of
E16 in the presence or absence of purified C1q
is summarized as described for (B). The average
of five experiments using at least four independent
preparations of RVPs is presented.
(D) To measure the ability of E16 to support ADE in
the presence or absence of C1q, complexes of
virus, antibody, and complement (where indicated) produced for the experiments described in (A) were also used to infect Fc-gR-expressing K562 cells. Infection
was expressed as infectivity relative to conditions in the absence of antibody. Error bars represent the standard error of the mean. Asterisks indicate statistical
significance as judged by a paired Student’s t test (**p% 0.01; ***p < 0.001).for their capacity to neutralize WNV in the presence and absence
of C1q. In the absence of C1q, all four subclasses of hu-E16
neutralized WNV at similar concentrations (Figures S5A–S5D).
In contrast, the potency of hu-E16 of different subclasses was
markedly different in the presence of human C1q. Subclasses
of hu-E16 that bind C1q avidly (hu-IgG1 and hu-IgG3) augmented
neutralization to a greater degree than subclasses that bind C1q
poorly (hu-IgG2 and hu-IgG4). C1q also increased the capacity of
both hu-IgG1 and hu-IgG3 subclasses of E16 to neutralize the
resistant fraction of 25% WT RVPs, albeit to differing degrees
(Figure 2C). In the presence of C1q, the fraction of virions resis-
tant to neutralization by saturating concentrations of the hu-IgG1
and hu-IgG3 subclasses of E16 was reduced by2- and8-fold,
respectively (p = 0.001, n = 5; and p = 0.002, n = 5, respectively).
C1q Reduces the Stoichiometric Threshold for
Neutralization below the Minimal Number of Antibodies
Required for ADE
ADE of infection and virus neutralization are two phenomena
related by the number of antibodies bound to the virion (Morens
et al., 1987; Pierson et al., 2007). Subneutralizing concentrations
of antibody augment infection of Fc-gR-expressing cells princi-
pally by enhancing the efficiency of virus attachment (Gollins
and Porterfield, 1984; Halstead, 2003) (C.A.J. and T.C.P., unpub-
lished data). ADE is most readily observed on cells that bind virus
poorly; expression of attachment factors (e.g., DC-SIGN) that
increase the efficiency of virus binding reduce the magnitude
of ADE (Boonnak et al., 2008; Pierson et al., 2007). Our previous
work suggests that in the absence of serum complement, ADE of384 Cell Host & Microbe 6, 381–391, October 22, 2009 ª2009 Elseviethe Fc-gRII-expressing cell K562 is possible at concentrations of
antibody that allow engagement of WNV virions by 15–30 Abs
(Pierson et al., 2007). Recent studies suggest that this relation-
ship is markedly different in the presence of complement. C1q
restricts ADE in an isotype-dependent fashion; antibodies that
bind C1q avidly do not support robust ADE of Fc-gRII-express-
ing K562 cells at any concentration (Mehlhop et al., 2007)
(Figure 2D).
How C1q modulates ADE has not been investigated in mech-
anistic terms. Because C1q and Fc-gR bind overlapping regions
of the antibody heavy chain (Duncan and Winter, 1988; Sonder-
mann et al., 2000), C1q may block ADE by competing with Fc-gR
for binding to virion-antibody complexes and preventing the
enhanced cellular attachment. Competition studies confirmed
that soluble Fc-gR could displace C1q bound to E protein
immune complexes on a biosensor chip (Figure S6). Despite
the potential competition between C1q and Fc-gR for antibody
binding, the lack of ADE in the presence of C1q was not due to
an inability of virions to attach to cells. In the presence of C1q,
binding of RVPs to Fc-gRII-expressing K562 cells was paradox-
ically enhanced over a relatively broad range of antibody con-
centrations, despite the lack of enhanced infection (Figure S7).
This binding pattern was also observed with Raji and Vero cells
(Figure S7, data not shown), indicating the phenomenon was
Fc-gR independent and possibly mediated by one or more of
the panoply of cellular factors that function as C1q receptors
(Ghebrehiwet et al., 1994). Exploring whether C1q restricts entry
of virion-antibody complexes through the Fc-gR pathway, and if
this is a requirement for ADE, will be of interest as a more detailedr Inc.
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Antibodies that Recognize Poorly Acces-
sible Determinants on WNV
The efficiency of the maturation of WNV RVPs was
manipulated as described previously (Nelson
et al., 2008). To reduce the efficiency of virion
maturation (immature WNV), WNV RVPs were
produced in the presence of ammonium chloride
(NH4Cl, 20 mM); an increase in maturation effi-
ciency (mature WNV) was achieved by transfec-
tion of RVP-producing cells with a plasmid that
expresses the human furin protease. Serial dilu-
tions of the fusion loop-reactive mAb E53 were mixed with RVPs produced using standard approaches (standard WNV, left panel), mature WNV preparations
(center panel), and immature WNV preparations (right panel) in the presence (red curves) or absence (blue curves) of purified human C1q protein prior to infection
of Raji-DC-SIGNR cells. Forty hours later, cells were fixed and analyzed by flow cytometry for GFP expression. The results are representative of two to three
independent experiments.picture of the virus entry pathway in Fc-gR-bearing cells
emerges.
Because of the established relationship between the concen-
trations of antibody that neutralize and enhance flavivirus infec-
tion (Morens et al., 1987; Pierson et al., 2007; Yamanaka et al.,
2008), insight into the mechanism by which C1q blocks ADE
can be inferred from changes in the requirements for neutraliza-
tion. A reduction in the number of antibodies required for neutral-
ization impacts the potential for ADE; lowering the stoichiometric
threshold for neutralization below the 15 mAbs required for
ADE would prevent enhancement of Fc-gRII-expressing cells
at any concentration of antibody. If neutralization of WNV in the
presence of C1q occurs when fewer than 15 mAbs are bound
to the virion, as our data suggest, the number of antibodies
bound to the virus at nonneutralizing concentrations of antibody
would never be sufficient to support ADE (Figure S3). Because
virions decorated with otherwise enhancing concentrations of
antibody still bind Fc-gRII-expressing cells in the presence of
C1q, the significant reduction in ADE in the presence of comple-
ment is likely explained by a reduction in the stoichiometric
threshold for neutralization below the minimal requirements for
enhanced infection rather than competition between C1q and
Fc-gRs for binding to antibodies bound to the virus particle.
C1q Promotes Antibody Neutralization of Virions that
Are Otherwise Resistant Because They Display Too Few
Epitopes
Not all mAbs recognize epitopes that are displayed on the
average WNV virion with a frequency that allows for neutraliza-
tion even when fully engaged (Nelson et al., 2008; Stiasny
et al., 2006). As an additional layer of complexity, populations
of flavivirus virions are heterogeneous with respect to the effi-
ciency of virus maturation (Davis et al., 2006; Guirakhoo et al.,
1992). The conformational changes in the E protein during virus
maturation impact epitope accessibility and neutralization sensi-
tivity (Guirakhoo et al., 1992; Nelson et al., 2008). Indeed, several
groups of mAbs that recognize structurally distinct epitopes fail
to neutralize mature WNV because virion maturation reduces
epitope accessibility to levels that do not support neutralization
(Nelson et al., 2008). Dose-response experiments performed
with domain II-fusion loop (DII-FL)-specific mAbs revealed matu-
ration state-dependent neutralization (Figure 3 and Figure S8);
increasing the efficiency of virion maturation identifies a popula-Cell Hotion of virions resistant to neutralization by saturating concentra-
tions of antibody as described previously (Nelson et al., 2008).
Notably, the addition of C1q increased E53-mediated neutraliza-
tion of this resistant fraction of virions (Figure 3), analogous to our
experiments that genetically manipulate the number of E16
epitopes on the virion. These data are consistent with a model
in which C1q augments the inhibitory potency of antibodies by
reducing the stoichiometric requirements for virus neutralization.
Crosslinking of Antibody Bound to WNV Is Sufficient to
Lower the Stoichiometric Threshold for Neutralization
C1q is a hexameric protein that binds most efficiently to anti-
bodies bound to repetitive arrays of antigens; the strength of
these multivalent interactions is significantly greater (1000-
fold) than monomeric binding (Burton, 1985; Duncan and Winter,
1988; Kishore and Reid, 2000). This raises the possibility that
C1q could augment neutralization by crosslinking E proteins on
a single virion, which could prevent conformational changes in
E required for virus entry and fusion. While a methodology to
manipulate the number of antibodies that an individual C1q
protein can bind has not been described, we assessed whether
crosslinking antibodies on the virion is sufficient to reduce the
stoichiometric requirements for neutralization. Incubation of
E16-virion complexes with intact antibodies or Fab2 fragments
of anti-murine IgG completely neutralized the resistant fraction
observed using RVPs composed of 25% WT E proteins, whereas
Fab fragments of anti-murine Ig had only a modest effect
(Figure 4). As C1q enhanced antibody neutralization using virions
with a defined and limited number of epitopes, our results cannot
be explained by a simple increase in antibody avidity. Instead,
our results suggest that the capacity to crosslink antibodies on
the virion is sufficient to reduce the stoichiometric requirements
for neutralization.
C1q-Mediated Increases in Neutralization Potency In
Vitro Correspond to an Increase in Protective Capacity
In Vivo
To determine if changes in the stoichiometric requirements for
neutralization translate into an increased capacity to protect
against lethal WNV challenge in vivo, WT or C1q/ mice were
passively administered limiting doses of IgG1, IgG2, or IgG3
subclass variants of hu-E16 1 day prior to WNV infection and
monitored for survival. Although transfer of all three hu-E16st & Microbe 6, 381–391, October 22, 2009 ª2009 Elsevier Inc. 385
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the concentration of antibody that protects 50% of animals
from mortality (IC50) were observed (Figure 5). Much of the
disparity in IC50 values among IgG subclasses (e.g., hu-E16
IgG2) is likely explained by differential binding to specific acti-
vating Fc-gR, which contribute to E16-mediated protection
against WNV infection in vivo (Oliphant et al., 2005).
However, we also observed a contribution of C1q to protection
by specific human IgG subclasses in mice. Protection by the hu-
E16 IgG3, which most avidly binds C1q, was observed at
increased concentrations in C1q/ compared to WT mice (p =
0.001, n R 14 mice/dose). The 5.5-fold decrease in antibody
potency in the absence of C1q in vivo was of similar magnitude
to the 6-fold increase in neutralization observed in vitro with the
IgG3 variant of E16 in the presence of fresh mouse sera
(Figure S5). In contrast, no significant difference in the IC50 of
hu-E16 IgG2 was observed between WT and C1q
/ mice (p =
0.8, n R 15 mice/dose). Interestingly, and consistent with data
from a SHIV challenge experiment (Hessell et al., 2007), no
statistical difference in the IC50 of hu-E16 IgG1 was observed
in WT and C1q/ mice (p = 0.4, nR 13 mice/dose; Figure 5).
To gain further support for an in vivo role for C1q in antibody-
mediated protection, we generated a point mutation (A330L) in
the CH2 domain of hu-E16 IgG3 that abolishes C1q binding but
retains Fc-gR binding (Figure S9). In vitro studies with the
A330L hu-E16 IgG3 variant demonstrated an improvement in
neutralizing activity (EC50 = 1.2 3 10
11 M and 1.9 3 1010 M
for hu-IgG3 A330L and hu-IgG3, respectively; n = 3). While the
improved neutralization activity of the A330L variant was unex-
pected, studies with anti-Cryptococcus antibodies indicate that
changes in the immunoglobulin constant region can impact
affinity and neutralizing activity (Torres and Casadevall, 2008).
Thus, a direct comparison of the A330L and the parent hu-E16
IgG3 was not possible because of their inherent difference in
neutralizing activity. However, and in contrast to the parent
hu-E16 IgG3, which showed a difference in IC50 in WT and
C1q/ mice, passive transfer studies with the A330L variant in
WT and C1q/ mice demonstrated no significant difference in
Figure 4. Crosslinking of Antibody Bound to WNV Is Sufficient to
Lower the Stoichiometric Threshold for Neutralization
WNV RVPs composed of 25% WT E proteins were incubated with serial 4-fold
dilutions of murine E16 in the absence or presence of anti-murine antibody-
specific IgG, Fab2, or Fab (2 mg/ml). RVP-antibody complexes were used to
infect duplicate wells containing Raji DC-SIGNR cells. Infection was monitored
using flow cytometry as described in Figure 1. The size of the resistant fraction
observed at high concentrations of antibody was enumerated by nonlinear
regression analysis and is shown on the y axis. Error bars display the standard
error of the mean from two to three independent assays.386 Cell Host & Microbe 6, 381–391, October 22, 2009 ª2009 Elsevthe IC50 (p = 0.1, n R 11 mice/dose; Figure 5). Taken together,
these data suggest C1q improves the protective activity of WNV
neutralizing mAbs in vivo in an IgG subclass-restricted manner.
DISCUSSION
In this study, we explored how complement augments the
neutralization potency of antiviral antibodies. The addition of
purified human C1q protein in neutralization experiments was
sufficient to augment the potency of several classes of mAbs,
as well as antibodies present in WNV-immune sera. These
results agree with previously described cell culture experiments
with WNV (Della-Porta and Westaway, 1977, 1978), yellow
fever virus (Spector and Tauraso, 1969), and DENV (Yamanaka
et al., 2008) infections, which described augmentation of anti-
body neutralization by fresh serum or complement. Because
increased neutralization did not require lysis of the virion, we
investigated the basis for this phenomenon with respect to the
stoichiometric requirements for antibody-mediated neutraliza-
tion. ‘‘Multiple hit’’ models of neutralization suggest the number
of antibodies bound to a virion determines infectivity (Burnet
et al., 1937; Burton et al., 2001; Della-Porta and Westaway,
1978). In this regard, at least two factors determine how many
antibodies are bound to a virion at any given concentration
of antibody and whether this will exceed the stoichiometric
requirements for virus inactivation: antibody affinity and epitope
accessibility. Our results demonstrate that increases in antibody
affinity mediated by C1q are not sufficient to explain increases
in neutralization potency in the presence of complement.
Instead, our data support a model by which C1q also reduces
the threshold number of antibodies required for neutralization
of WNV.
The potency of several classes of antibodies is limited by the
accessibility of the epitope they recognize on the surface of
the virus particle (Nelson et al., 2008; Oliphant et al., 2006;
Stiasny et al., 2006). When epitopes are displayed on the virion
in small numbers, antibodies that recognize them fail to
neutralize infectivity at any concentration because the total
Figure 5. C1q Augments hu-E16-Mediated Protection In Vivo
WT and C1q/ mice were passively transferred with serial 10-fold reductions
in dose (ranging from 67 to 0.067 mg/kg) of E16 subclass-switch variants hu-
IgG1 (nR 13 mice/dose), hu-IgG2 (nR 15 mice/dose), hu-IgG3 (nR 14 mice/
dose), and an A330L variant of E16 hu-IgG3 (IgG3 A330L) (nR 11 mice/dose)
1 day prior to infection with 102 PFU of WNV and subsequently monitored for
morbidity. Survival data from at least three independent experiments were
analyzed by log-rank test, and IC50s were calculated by nonlinear regression
of survival percentage at each mAb dose. Error bars represent the standard
error of the mean. Asterisks indicate statistical significance as judged by anal-
ysis of variance and an F test (**p = 0.001).ier Inc.
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exceed the requirements for neutralization. The neutralization
potency of antibodies specific for the DII-FL is limited by
the poor accessibility of this epitope on mature flavivirus
virions (Nelson et al., 2008; Oliphant et al., 2006; Stiasny
et al., 2006). In this context, viruses resistant to neutralization
at saturating concentrations of antibody represent virus particles
that do not display enough epitopes to allow for neutralization by
antibodies of that specificity. For WNV, the efficiency of the
maturation process strongly impacts neutralization sensitivity
by modulating epitope accessibility (Nelson et al., 2008). In a
similar fashion, genetic methods that reduce the number of
epitopes on the average virion also allow for the production of
viruses resistant to neutralization. In this system, the size of the
fraction of virions resistant to neutralization by saturating
concentrations of antibody is inversely related to the number of
intact epitopes on the average virion in the population (Pierson
et al., 2007). In these two complementary experimental models,
the ability of C1q to promote neutralization of the resistant frac-
tion of viruses cannot be explained by increases in antibody
affinity because, in both cases, it is the number of epitopes on
these virus particles that is limiting. In the presence of saturating
concentrations of antibody, there are no additional sites for anti-
bodies to bind.
The complement-mediated reduction in the number of anti-
bodies required for neutralization has significant implications
for humoral immunity to flavivirus infection. First, a lower stoi-
chiometric threshold allows inactivation of virus particles that
would otherwise be resistant to neutralization by antibodies
specific for poorly accessible epitopes. A significant proportion
of human antibodies elicited by flavivirus infection recognize
the DII-FL (Crill et al., 2007; Lai et al., 2008; Oliphant et al.,
2006; Throsby et al., 2006). Antibodies specific for this poorly
accessible epitope exhibit limited potency in vitro (Oliphant
et al., 2006; Stiasny et al., 2006) and may be sensitive to the
maturation state of the virus particle (Figure 3). In the absence
of complement, the protective capacity of these antibodies
may depend in part on the composition of the virus. Mature
WNV has been shown to be significantly less sensitive to neutral-
ization by DII-FL-specific mAbs and polyclonal WNV-immune
sera obtained from roughly 50% of the recipients of two candi-
date WNV vaccines (Nelson et al., 2008). A reduced stoichio-
metric requirement for neutralization in the presence of comple-
ment increases the fraction of virus particles sensitive to
neutralization by DII-FL-specific antibodies and may explain
why polyclonal responses composed of antibodies with this
specificity still can be protective in vivo.
Changes in the neutralization potency of antibodies also
impact their potential to enhance flavivirus infection. Recent
studies have shown that complement significantly reduces
the capacity for antibodies to promote ADE via undefined mech-
anisms (Mehlhop et al., 2007; Yamanaka et al., 2008). Because
antibody-mediated neutralization of infection and ADE are
two outcomes related by the number of antibodies bound
to the virion (Morens et al., 1987; Pierson et al., 2007), a reduc-
tion in the number of antibodies required for neutralization
should impact ADE. Surprisingly, despite significant changes in
neutralization potency (EC50) in the presence of C1q (Figures
1A and 2A), a corresponding change in the concentrations atCell Hoswhich ADE occurs was not observed (Figure 2D and Mehlhop
et al., 2007). Instead, C1q restricted ADE almost completely.
Mechanistically, this is explained as follows: C1q enhances
neutralization by changing the number of antibodies required
for virus inactivation, rather than the number of antibodies
bound to the virion at a given concentration (e.g., avidity). For
K562 cells expressing activating Fc-gRIIA receptors, ADE
occurs when roughly 15–30 antibodies engage WNV. For IgG
subclasses (e.g., murine IgG2b or hu-IgG3) that bind C1q avidly,
the neutralization threshold in the presence of C1q falls below
the minimal stoichiometric requirements for ADE and explains
why C1q restricts ADE in an IgG subclass-specific manner
(Figure S3).
An ability to directly enhance neutralization is consistent with
a protective role for complement after infection by WNV, and
likely other flaviviruses. Mice deficient in components of the clas-
sical, lectin, or alternative complement activation pathways all
showed increased WNV replication and lethality after infection
(Mehlhop and Diamond, 2006; Mehlhop et al., 2005). Immuno-
logical analysis revealed that in many of the complement-defi-
cient strains of mice used in these studies, the phenotype was
related to complement’s function in priming of adaptive B and
T cell responses. Nonetheless, C1q/ mice showed increased
vulnerability to WNV infection despite relatively intact B and
T cell responses, suggesting an independent protective effect,
possibly through interaction with complement-fixing antibodies
(Mehlhop and Diamond, 2006). The neutralization and protection
studies with deficient serum and mice establish a C1q-depen-
dent antibody protective mechanism. More recent studies
have confirmed that C1q-dependent protection by comple-
ment-fixing anti-WNV antibodies does not require membrane
attack complex deposition or virolysis in vivo, as a similar IC50
of E16 is observed in C5/ and WT mice (Mehlhop et al.,
2009). Thus, C1q is the critical complement component that
modulates antibody potency against WNV; as such, its inclusion
in flavivirus serum neutralization titration assays may improve the
correlation between in vitro neutralizing activity and in vivo
protection.
Enhancement of antibody-mediated neutralization by comple-
ment is not unique to flaviviruses. The addition of complement
to in vitro assays has been shown to augment neutralization
by antiviral antibodies of several families of RNA and DNA
viruses (reviewed in Carroll, 2004; Zinkernagel et al., 2001).
However, few studies have defined the complement compo-
nents that mediate this effect and the mechanism of action.
For example, the first four components of the classical path-
way were shown as necessary for the increasing antibody-
mediated neutralization of Newcastle disease virus (Linscott
and Levinson, 1969), hepatitis C virus (Meyer et al., 2002), HIV
(Sullivan et al., 1998), and HSV (Daniels et al., 1969, 1970).
Complement-dependent antibody neutralization of vaccinia
virus was augmented in C5- but not C3-depleted serum;
thus, coating and opsonization, rather than virolysis, have
been postulated as an explanation for the enhanced neutralizing
activity (Rafii-El-Idrissi Benhnia et al., 2008). In contrast,
complement-triggered virolysis contributes to the augmented
antibody-dependent neutralization of HIV and parainfluenza
virus in vitro (Spear et al., 1993; Vasantha et al., 1988). Comple-
ment-enhanced antibody neutralization of influenza virus in vitrot & Microbe 6, 381–391, October 22, 2009 ª2009 Elsevier Inc. 387
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nowska et al., 2006).
Our studies demonstrate a strict isotype requirement for
improved antibody neutralization of WNV, results that agree
with in vitro investigations with influenza virus (Feng et al.,
2002; Mozdzanowska et al., 2006) and in vivo studies with
neutralizing yellow fever virus antibodies that showed enhanced
protection correlated with IgG subclasses that efficiently fix
complement (Schlesinger and Chapman, 1995). Antibody iso-
types that bind C1q poorly (e.g., mIgG1, hu-IgG2, and hu-IgG4)
showed no enhanced neutralization in the presence of C1q or
serum in vitro. Moreover, the experiments with the C1q avid
hu-E16 IgG3 in WT and C1q
/ mice show that C1q affects
an 5.5-fold change in the IC50 of antibody protection, similar
in magnitude to the enhanced neutralizing activity observed
in vitro with murine C1q (6-fold) or human C1q (19-fold)
(Figure S5). To our knowledge, this is the first direct demonstra-
tion of C1q changing the potency of an antibody in vivo. Indeed,
despite a prominent effect in vitro (Feng et al., 2002; Mozdza-
nowska et al., 2006), C1q did not contribute to the prophylactic
activity of anti-influenza neutralizing mAbs in vivo (Mozdzanow-
ska et al., 2006). The isotype-dependent improvement of
antibody potency in vivo may also, in part, clarify why comple-
ment does not augment the protection conferred by passive
transfer of an HIV-specific human IgG1 mAb (Hessell et al.,
2007), as this subclass binds C1q less efficiently than human
IgG3 mAbs (Bindon et al., 1988). Similarly, we did not observe
a change in protection of the hu-E16 IgG1 in C1q
/ mice.
One caveat to this analysis is that given the small shift in neutral-
ization potency in vitro of hu-E16 IgG1 in the presence of
C1q (Figure S5; 2.5- and 1.1-fold for human and murine C1q,
respectively), a larger number of animals (n = 21 mice per each
antibody dose for a 2-fold effect) would be required to obtain
sufficient statistical power to conclude definitively that C1q has
no effect on the protective activity hu-E16 IgG1 in vivo. Finally,
structural differences between retroviruses and flaviviruses,
coupled with the ability of the latter to incorporate comple-
ment-modulating cellular factors, may add to the complexity of
this comparison.
In summary, we have established a biochemical mechanism
by which the complement component C1q increases the neutral-
izing activity of antibodies. In addition, we suggest these mech-
anistic insights have practical consequences with broad applica-
tions. In general, a goal of vaccination is to produce high-affinity
neutralizing antibodies. However, the cryptic properties of
epitopes commonly elicited by infection and the heterogeneous
nature of flaviviruses may limit the efficacy of antibodies regard-
less of the strength with which they bind virions. Our recent
studies indicate that humans infected with WNV or vaccinated
with WNV noninfectious particles dominantly develop IgG1
anti-WNV responses (E.M. and M.S.D., unpublished data). More-
over, some patients associated with severe DENV infection
have high levels of noncomplement-fixing IgG4 anti-DENV anti-
bodies (Koraka et al., 2001). As C1q can alter the stoichiometric
requirements for neutralization, vaccine strategies that use
adjuvants that favorably skew IgG subclass responses to C1q-
fixing IgG subclasses may elicit more protective antiviral anti-
bodies. Moreover, engineering therapeutic antiviral antibodies
against flaviviruses with improved C1q-binding properties388 Cell Host & Microbe 6, 381–391, October 22, 2009 ª2009 Elsevishould enhance neutralization potency and limit the potential
for ADE.
EXPERIMENTAL PROCEDURES
Cells, RVPs, and Antibodies
HEK293T, BHK21, C6/36, K562, and Raji-DC-SIGNR cells were maintained as
described previously (Pierson et al., 2005, 2006, 2007). WNV RVPs were
produced in HEK293T or BHK21 cells as described (Pierson et al., 2006,
2007). Methods to manipulate the number of DIII-LR epitopes on WNV RVPs
(Pierson et al., 2007), modulate the efficiency of virion maturation (Nelson
et al., 2008), and generate the human IgG subclass variants of E16 (Mehlhop
et al., 2007) have been described. The A330L variant of hu-E16 IgG3 was
generated by site-directed mutagenesis using the QuikChange Mutagenesis
Kit (Stratagene, La Jolla, CA).
WNV Neutralization and Enhancement Assays
The neutralization potency of antibodies or immune sera was measured in the
presence or absence of fresh sera or purified human C1q protein (Complement
Technologies, Tyler, TX) using a Raji B lymphoblastoid cell line that expresses
DC-SIGNR as described (Mehlhop et al., 2007; Pierson et al., 2006, 2007).
Neutralization potency was calculated as a function of the concentration of
antibody required to block 50% of the infection events using nonlinear
regression analysis (GraphPadPrism4, San Diego, CA). All neutralization
studies were performed using conditions designed to satisfy the ‘‘percentage
law’’ (Andrewes and Elford, 1933).
In Vivo Protective Efficacy
All mice were housed in a pathogen-free mouse facility at Washington Univer-
sity School of Medicine. Studies were performed in compliance with the guide-
lines of the Washington University School of Medicine Animal Safety
Committee. All mice received affinity-purified mAb by intraperitoneal injection
1 day prior to footpad infection with 102 plaque-forming units (PFUs) of WNV
isolate 3000.0259 that was propagated once in C6/36 cells. Five-week-old
WT C57BL/6 mice were purchased commercially (Jackson Laboratories, Bar
Harbor, ME). Congenic C1q/ mice were bred at Washington University and
infected with WNV at 8–10 weeks of age, resulting in a baseline mortality rate
similar to that of 5-week-old WT mice. Kaplan-Meier analysis of survival data
was performed using the log-rank test and Prism software (GraphPadPrism4,
San Diego, CA). IC50 analyses were performed by nonlinear regression, and
statistical significances were determined using analysis of variance (ANOVA)
and F tests.
Surface Plasmon Resonance Analysis of Fc-gR and C1q Binding to
hu-E16 IgG3
The binding of human FcgRs and C1q to the hu-E16 IgG3 Fc was analyzed by
surface plasmon resonance (SPR) using a BIAcore 3000 biosensor (BIAcore,
Uppsala, Sweden). WNV DIII was immobilized on the CM-5 sensor chip by
amine-coupling kit as recommended by the manufacturer. A surface treated
with amine-coupling reagents was used as a blank. Binding experiments were
performed in HBS-EP buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 3 mM
EDTA, and 0.005% P20 surfactant). WT or variant antibody was bound to the
DIII surface at approximately 1000 RU followed by injection of soluble Fc-gRs:
human CD32A-131His or Arg-G2, N297Q (Stavenhagen et al., 2007) at
a concentration of 100 nM or C1q at 24 nM and a flow rate of 30 ml/min for
60 s with dissociation time of 60 s. Each receptor or C1q was injected in dupli-
cate. Between injections within an experiment, bound Fc-gR was completely
dissociated using 1 M ethanolamine-HCl (pH 8.5). Between experiments, the
naked antigen surface was regenerated by pulse injection of 10 mM glycine
pH 1.5. Binding responses were normalized to the level of captured WT
hu-E16 IgG3 antibody.
SUPPLEMENTAL DATA
Supplemental Data include nine figures and can be found with this
article online at http://www.cell.com/cell-host-microbe/supplemental/S1931-
3128(09)00312-6.er Inc.
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